Acta Radiol: 前列腺肿瘤放射治疗后的监测研究

2018-09-26 AlexYang MedSci原创

放射治疗后效果的纵向监测可以通过动态超声造影成像(DCE-US)来实现。最近,有研究人员利用DCE-US在一个人类前列腺癌小鼠皮下模型中评估了相关的功能性参数,并且探究了治疗后剂量累计和时间时限的相关性。另外,研究人员还特别关注且评估了肿瘤的血管异质性,并利用了最合适的数据分析方法来反应上述异质性。研究人员在 7.5 Gy和10 Gy单独剂量放射治疗后的24小时和48小时时分别获得了DCE-US数

放射治疗后效果的纵向监测可以通过动态超声造影成像(DCE-US)来实现。最近,有研究人员利用DCE-US在一个人类前列腺癌小鼠皮下模型中评估了相关的功能性参数,并且探究了治疗后剂量累计和时间时限的相关性。另外,研究人员还特别关注且评估了肿瘤的血管异质性,并利用了最合适的数据分析方法来反应上述异质性。

研究人员在 7.5 Gy和10 Gy单独剂量放射治疗后的24小时和48小时时分别获得了DCE-US数据。研究发现,在放射治疗24小时和48小时时检测到了显著的纵向变化(P<0.001)。在48小时时,治疗组造影剂的消除速率常数与微血管密度 (MVD; rτ=0.7) 呈现正相关关系(P  ≤ 0.05),并且与坏死(rτ=-0.6)呈现负相关关系。更进一步的是,Akep,一个与经毛细血管传输特性恶性相关的参数,与MVD也相关(rτ=0.6, P ≤ 0.05)。

最后,研究人员指出,DCE-US能够在放射治疗后的早期阶段检测血管变化,这是一个非常大的优势,并且DCE-US没有侵入性,在大多医院均可以使用。另外,与临床实践其他技术相比花费较低。

原始出处:

Arteaga-Marrero N, Mainou-Gomez JF, Brekke Rygh C et al. Radiation treatment monitoring with DCE-US in CWR22 prostate tumor xenografts. Acta Radiol. Sep 19 2018.

本文系williamhill asia 医学(MedSci)原创编译和整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771469, encodeId=d6bb1e71469ca, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Thu Sep 27 06:36:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849617, encodeId=b571184961e19, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Sep 05 22:36:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018053, encodeId=e54420180538c, content=<a href='/topic/show?id=8fba8295380' target=_blank style='color:#2F92EE;'>#肿瘤放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82953, encryptionId=8fba8295380, topicName=肿瘤放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 19 23:36:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346938, encodeId=f7a53469381d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Sep 27 18:31:45 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346740, encodeId=cbc7346e40f7, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 26 12:47:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771469, encodeId=d6bb1e71469ca, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Thu Sep 27 06:36:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849617, encodeId=b571184961e19, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Sep 05 22:36:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018053, encodeId=e54420180538c, content=<a href='/topic/show?id=8fba8295380' target=_blank style='color:#2F92EE;'>#肿瘤放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82953, encryptionId=8fba8295380, topicName=肿瘤放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 19 23:36:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346938, encodeId=f7a53469381d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Sep 27 18:31:45 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346740, encodeId=cbc7346e40f7, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 26 12:47:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2019-09-05 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771469, encodeId=d6bb1e71469ca, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Thu Sep 27 06:36:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849617, encodeId=b571184961e19, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Sep 05 22:36:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018053, encodeId=e54420180538c, content=<a href='/topic/show?id=8fba8295380' target=_blank style='color:#2F92EE;'>#肿瘤放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82953, encryptionId=8fba8295380, topicName=肿瘤放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 19 23:36:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346938, encodeId=f7a53469381d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Sep 27 18:31:45 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346740, encodeId=cbc7346e40f7, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 26 12:47:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771469, encodeId=d6bb1e71469ca, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Thu Sep 27 06:36:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849617, encodeId=b571184961e19, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Sep 05 22:36:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018053, encodeId=e54420180538c, content=<a href='/topic/show?id=8fba8295380' target=_blank style='color:#2F92EE;'>#肿瘤放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82953, encryptionId=8fba8295380, topicName=肿瘤放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 19 23:36:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346938, encodeId=f7a53469381d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Sep 27 18:31:45 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346740, encodeId=cbc7346e40f7, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 26 12:47:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-27 一个字-牛

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1771469, encodeId=d6bb1e71469ca, content=<a href='/topic/show?id=3e0432563e5' target=_blank style='color:#2F92EE;'>#前列腺肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32563, encryptionId=3e0432563e5, topicName=前列腺肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=257238300920, createdName=gous, createdTime=Thu Sep 27 06:36:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849617, encodeId=b571184961e19, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Sep 05 22:36:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018053, encodeId=e54420180538c, content=<a href='/topic/show?id=8fba8295380' target=_blank style='color:#2F92EE;'>#肿瘤放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82953, encryptionId=8fba8295380, topicName=肿瘤放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Aug 19 23:36:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346938, encodeId=f7a53469381d, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Sep 27 18:31:45 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346740, encodeId=cbc7346e40f7, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Sep 26 12:47:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-26 惠映实验室

    学习了,谢谢分享。

    0

相关威廉亚洲官网

盘点:前列腺疾病研究进展

【1】Clin Cancer Res:前列腺癌液体活检样本的单细胞分析 研究表明,循环肿瘤细胞(CTCs)具有临床相关性,但是由于它们出现的频率低,限制了人们对它的研究。最近,有研究人员通过清血法(Ahperesis)来增加CTC的产量,对患有转移性性前列腺癌的患者进行了液体活检评估,并进行了精确的基因拷贝数计算和疾病遗传与异质性研究。研究发现,清血法具有良好的耐受性,并且能够分离大

盘点:前列腺与遗传研究进展

【1】Cancer Lett:TMPRSS2:ERG基因融合表达能够调控骨标记和增强前列腺癌骨转移成骨细胞表型 前列腺癌具有很强的转移到骨组织的倾向性,并且促进成骨细胞病变。TMPRSS2:ERG是前列腺癌中最常见的基因重排,但是是否该基因重排参与前列腺癌骨转移仍旧未知。最近,有研究人员探索了一个转移模型来探究上述问题,并且发现,TMPRSS2:ERG融合基因的异位表达能够增强前列腺

盘点:前列腺与治疗盘点

【1】Clin Cancer Res:前列腺癌荧光指导的手术中,新型前列腺特异性膜抗原靶向近红外成像剂评估 https://www.ncbi.nlm.nih.gov/pubmed/30201762在根治性前列腺切除手术中准确定位和移除所有恶性病变部位不仅能够阻止生化复发(BCR)和可能的副作用,同时也能够改善前列腺癌患者(PCa)的生活期望。荧光指导的手术(FGS)作为一种新的技术,主要利用荧

Prostate Cancer P D:良性前列腺增生中,双极等离子前列腺剜除术与开放前列腺切除术比较

最近,有研究人员在一个单中心群体研究的前列腺肥大(>80g)患者中比较了双极等离子前列腺剜除术与开放前列腺切除术的手术治疗结果和安全性。所有由于良性前列腺增生而患有下尿路症状的患者在2012年5月和2013年12月之间均经历双极等离子前列腺剜除术(TUEP)或者开放前列腺切除术(OP)。研究人员在术后的0, 1, 3, 6, 12, 24和36个月时对临床历史、身体检查、尿路症状、阴茎勃起功

Sci Rep:下尿路症状/良性前列腺增生治疗中,α-受体阻滞剂处方方式研究

最近,有研究人员在治疗患有BPH患者中,调查了α-受体阻滞剂在处方中的趋势情况,并且利用国家健康保险服务中的国家样本群体数据,关注了2002年到2013年处方方式的变化情况。研究包括了年龄大于50岁的65596名诊断为BPH的韩国男性,他们均从2002年到2013年之间的NHIS-NSC数据库中鉴定得到。研究人员分析了每一种α-受体阻滞剂的处方方式,并推算了首次处方后为期3年跟踪调查的持久率、转化

CSCO2018大家访谈录│周芳坚教授:打好前列腺精准治疗的攻坚战

第二十一届全国临床肿瘤大会暨2018年CSCO学术年会热度持续走高,现整理中山大学附属肿瘤医院周芳坚教授分享的前列腺癌精准诊疗的发展现状和挑战的相关内容。